PMID- 24510380
OWN - NLM
STAT- MEDLINE
DCOM- 20140708
LR  - 20211021
IS  - 1934-6638 (Electronic)
IS  - 1934-662X (Print)
IS  - 1934-662X (Linking)
VI  - 122
IP  - 5
DP  - 2014 May
TI  - Optimizing detection of RET and PPARg rearrangements in thyroid neoplastic cells 
      using a home-brew tetracolor probe.
PG  - 377-85
LID - 10.1002/cncy.21397 [doi]
AB  - BACKGROUND: Fluorescence in situ hybridization (FISH) to identify specific DNA 
      target sequences in the nuclei of nondividing cells of numerous solid neoplasms 
      has contributed to the introduction of molecular cytogenetics as a useful adjunct 
      to cytology, leading recently to the "marriage" of the 2 disciplines. Numerous 
      cancer molecular markers can now be investigated using different technical 
      approaches, at both the gene and expression levels, in biopsies of various 
      suspected cancers, including differentiated thyroid carcinoma. The limited amount 
      of bioptic material is often insufficient to carry out multiple tests, and 
      optimizing handling of the biopsy is desirable. METHODS: We have developed a 
      home-brew tetracolor break-apart probe able to simultaneously identify the 2 most 
      common genetic alterations in differentiated thyroid carcinoma: RET/PTC variants 
      in papillary thyroid carcinoma and PAX8/PPARg fusion and variants in follicular 
      thyroid carcinoma. RESULTS: The probe had 100% specificity, 99.5% sensitivity, 
      and >/= 3% cutoff. The probe was tested on RET/PTC and PAX8/PPARg RT-PCR positive 
      controls, and feasibility was assessed in 368 thyroid nodule fine-needle 
      aspirations (FNA). In the latter analysis, 24 FNAs had split RET signal, and 9 
      had split PPARg signal. FISH analysis of available surgically removed nodules 
      confirmed the sensitivity of FISH in detecting abnormal clones and oligoclones. 
      CONCLUSIONS: The home-brew tetracolor probe showed high feasibility, optimizing 
      the use of the biological material in relation to the available molecular tests 
      and maximizing the FISH experimental and slide-scoring times. This probe may be 
      considered an alternative to RT-PCR when recovery and quality of RNA 
      amplification from FNA are insufficient.
CI  - (c) 2014 The Authors. Cancer Cytopathology published by Wiley Periodicals, Inc. on 
      behalf of American Cancer Society.
FAU - Caria, Paola
AU  - Caria P
AD  - Department of Biomedical Sciences, University of Cagliari, Cagliari, Italy.
FAU - Frau, Daniela V
AU  - Frau DV
FAU - Dettori, Tinuccia
AU  - Dettori T
FAU - Boi, Francesco
AU  - Boi F
FAU - Lai, Maria L
AU  - Lai ML
FAU - Mariotti, Stefano
AU  - Mariotti S
FAU - Vanni, Roberta
AU  - Vanni R
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140207
PL  - United States
TA  - Cancer Cytopathol
JT  - Cancer cytopathology
JID - 101499453
RN  - 0 (Fluorescent Dyes)
RN  - 0 (PPAR gamma)
RN  - 0 (RNA, Messenger)
RN  - EC 2.7.10.1 (Proto-Oncogene Proteins c-ret)
RN  - EC 2.7.10.1 (RET protein, human)
SB  - IM
MH  - Adenocarcinoma, Follicular/genetics/pathology
MH  - Biopsy, Fine-Needle
MH  - Carcinoma, Papillary/genetics/pathology
MH  - Feasibility Studies
MH  - *Fluorescent Dyes
MH  - Follow-Up Studies
MH  - *Gene Rearrangement
MH  - Goiter, Nodular/genetics/pathology
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - PPAR gamma/*genetics
MH  - Prognosis
MH  - Proto-Oncogene Proteins c-ret/*genetics
MH  - RNA, Messenger/genetics
MH  - Reverse Transcriptase Polymerase Chain Reaction
MH  - Sensitivity and Specificity
MH  - Thyroid Neoplasms/*genetics/*pathology
PMC - PMC4231233
OTO - NOTNLM
OT  - FISH
OT  - FNA
OT  - PAX8/PPARg
OT  - RET/PTC
OT  - thyroid cancer
EDAT- 2014/02/11 06:00
MHDA- 2014/07/09 06:00
PMCR- 2014/11/14
CRDT- 2014/02/11 06:00
PHST- 2013/10/24 00:00 [received]
PHST- 2013/12/28 00:00 [revised]
PHST- 2014/01/01 00:00 [accepted]
PHST- 2014/02/11 06:00 [entrez]
PHST- 2014/02/11 06:00 [pubmed]
PHST- 2014/07/09 06:00 [medline]
PHST- 2014/11/14 00:00 [pmc-release]
AID - 10.1002/cncy.21397 [doi]
PST - ppublish
SO  - Cancer Cytopathol. 2014 May;122(5):377-85. doi: 10.1002/cncy.21397. Epub 2014 Feb 
      7.